Ranolazine attenuates behavioral signs of neuropathic pain

Harry J. Gould, Colleen Garrett, Renee R. Donahue, Dennis Paul, Ivan Diamond, Bradley K. Taylor

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Ranolazine modulates the cardiac voltage-gated sodium channel (NaV 1.5) and is approved by the FDA in the treatment of ischemic heart disease. Ranolazine also targets neuronal (NaV 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine in a preclinical animal model of neuropathic pain. Both intraperitoneal and oral administration of ranolazine dose-dependently inhibited the mechanical and cold allodynia associated with spared nerve injury, without producing ataxia or other behavioral side effects. These data warrant clinical investigation of the potential use of ranolazine in the treatment of neuropathic pain.

Original languageEnglish (US)
Pages (from-to)755-758
Number of pages4
JournalBehavioural Pharmacology
Issue number8
StatePublished - Dec 2009
Externally publishedYes


  • Allodynia
  • Hyperalgesia
  • Na 1.7
  • NaV 1.8
  • Rat
  • Spared nerve injury


Dive into the research topics of 'Ranolazine attenuates behavioral signs of neuropathic pain'. Together they form a unique fingerprint.

Cite this